Can Acrodermatitis Continua of Hallopeau with Moderate-to-Severe Nail Involvement Be Effectively Controlled? A Real-World, 24-Week Study of 17 Cases Treated via Periungual Injection of the Novel IL-17A Inhibitor Xeligekimab Combined with Tofacitinib (EADV 2026) - Aug 6, 2026 - Abstract #P2161; AS-1372; Pres time: Sep 30, 2026; Location: ePoster Area; "Conclusions This real-world study demonstrates that ACH with moderate-to-severe nail involvement can be effectively controlled through periungual xeligekimab combined with tofacitinib. It is a well-tolerated therapeutic strategy offering significant improvement in nail lesions."
Clinical • Real-world • Real-world evidence • Addiction (Opioid and Alcohol) • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Otorhinolaryngology • Psoriasis • Pustular Psoriasis • Respiratory Diseases • Sinusitis • IL17A
|
|
Anqi Liu 1; Zhiying Yu 1; Meng Wang 1; Shaohui Geng 2; Ying Yang 1; Chen Li 1
|